Tech Company Financing Transactions
Vita Therapeutics Funding Round
On 10/12/2022, Vita Therapeutics raised $31 million in Series B financing from Cambrian Biopharma, Solve FSHD and Cedars-Sinai Medical Center.
Transaction Overview
Company Name
Announced On
10/12/2022
Transaction Type
Venture Equity
Amount
$31,000,000
Round
Series B
Investors
Cambrian Biopharma (Lead Investor) (James Peyer)
Solve FSHD (Lead Investor)
Proceeds Purpose
Proceeds from the financing will be used to advance Vita's lead pre-clinical program VTA-100 for limb-girdle muscular dystrophy (LGMD2A) to the clinic. It will also fund the development of Vita's newest program, VTA-120 for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD), and to further expand Vita's discovery pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1209 Orange St.
Wilmington, DE 19801
USA
Wilmington, DE 19801
USA
Phone
Undisclosed
Website
Email Address
Overview
Vita Therapeutics utilizes iPSCs to engineer specific cell types that are designed to replace those that are defective in patients. To deliver these cells we focus on two distinct methodologies: the autologous approach, a patient-specific therapy, and a hypoimmunogenic approach, a universal cell designed to be used for all patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Falk
Co-Founder
Peter Andersen
VP - Regulatory Affairs
Steven Brooks
Browse more venture capital transactions:
Prev: 10/12/2022: Soli Organic venture capital transaction
Next: 10/12/2022: Axelor venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs